Critical Pathways for Acute Coronary Syndromes

  • Christopher P. Cannon
  • Patrick T. O’Gara
Part of the Contemporary Cardiology book series (CONCARD)


Critical pathways are standardized protocols for the management of specific disorders that attempt to optimize and streamline patient care. Numerous other names have been developed for such programs, including “clinical pathways” (so as not to suggest to patients that they are in “critical” condition), or simply “protocols,” such as the acute myocardial infarction (MI) protocols used in emergency departments to reduce time to treatment with thrombolysis (1,2). The broader term Disease Management is currently used to denote that these pathways extend beyond the hospital phase of treatment and to optimize medical management of diseases over the long term.


Acute Coronary Syndrome Acute Myocardial Infarction Unstable Angina Primary Angioplasty Critical Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis 1994; 1: 27–34.PubMedCrossRefGoogle Scholar
  2. 2.
    National Heart Attack Alert Program Coordinating Committee-60 Minutes to Treatment Working Group. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994; 23: 311–329.CrossRefGoogle Scholar
  3. 3.
    Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327: 175–181.PubMedCrossRefGoogle Scholar
  4. 4.
    Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–135.CrossRefGoogle Scholar
  5. 5.
    Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396–403.PubMedCrossRefGoogle Scholar
  6. 6.
    Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313: 1369–1375.PubMedCrossRefGoogle Scholar
  7. 7.
    Theroux P, Ouimet H, McCans J, Latour J-G, Joly G, Levy G, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988; 319: 1105–1111.PubMedCrossRefGoogle Scholar
  8. 8.
    The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–830.CrossRefGoogle Scholar
  9. 9.
    Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992; 19: 671–677.PubMedCrossRefGoogle Scholar
  10. 10.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–360.Google Scholar
  11. 11.
    Klimt CR, Knatterud GL, Stamler J, Meier P, for the PARIS II Investigator Group. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251–269.PubMedCrossRefGoogle Scholar
  12. 12.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death from myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.CrossRefGoogle Scholar
  13. 13.
    Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90: 2103–2114.PubMedCrossRefGoogle Scholar
  14. 14.
    Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, et al. Quality of care for medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995; 273: 1509–1514.PubMedCrossRefGoogle Scholar
  15. 15.
    Cannon CP, Moliterno DJ, Every N, Anderson HV, Aguirre FV, Granger CB, et al. Implementation of AHCPR guidelines for unstable angina in 1996: Unfortunate differences between men and women. Results from the multicenter GUARANTEE registry (abstract). J Am Coll Cardiol 1997; 29 (Suppl. A): 217A.Google Scholar
  16. 16.
    Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 997; 96: 2751–2753.Google Scholar
  17. 17.
    Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045–2048.PubMedCrossRefGoogle Scholar
  18. 18.
    Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation 1994; 89: 81–88.PubMedCrossRefGoogle Scholar
  19. 19.
    Oler A, Whooley MA, Oler J, Grady D. Adding heparin to asprin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811–815.PubMedCrossRefGoogle Scholar
  20. 20.
    FRISC Study Group. Low molecular weight heparin (Fragmin) during instability in coronary artery disease (FRISC). Lancet 1996; 347: 561–568.Google Scholar
  21. 21.
    Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, et al. A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–452.PubMedCrossRefGoogle Scholar
  22. 22.
    Bleich SD, Nichols T, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412–1417.PubMedCrossRefGoogle Scholar
  23. 23.
    Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433–1437.PubMedCrossRefGoogle Scholar
  24. 24.
    de Bono DP, Simoons MI, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122–128.PubMedCrossRefGoogle Scholar
  25. 25.
    Baird SH, McBride SJ, Trouton TG, Wilson C. Low-molecular-weight heparin versus unfractionated heparin following thrombolysis in myocardial infarction (abstract). J Am Coll Cardiol 1998; 31 (Suppl. A): 191A.CrossRefGoogle Scholar
  26. 26.
    Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328–1428.PubMedCrossRefGoogle Scholar
  27. 27.
    Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, et al. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10. Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, 1994.Google Scholar
  28. 28.
    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–677.PubMedCrossRefGoogle Scholar
  29. 29.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828.Google Scholar
  30. 30.
    Gruppo Italiano per to Studio della Sopravivenza nell’Infarto Miocardico. GISSI-3: effect of lisinopril and trasdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–1122.Google Scholar
  31. 31.
    ISIS-4 Collaborative Group. ISIS-4: randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–685.CrossRefGoogle Scholar
  32. 32.
    Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686–687.CrossRefGoogle Scholar
  33. 33.
    The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Circulation 1994; 89: 1545–1556.CrossRefGoogle Scholar
  34. 34.
    Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–322.Google Scholar
  35. 35.
    Braunwald E, Cannon CP. Non-Q wave and ST segment depression myocardial infarction: is there a role for thrombolytic therapy? (editorial). J Am Coll Cardiol 1996; 27: 1333–1334.PubMedCrossRefGoogle Scholar
  36. 36.
    Cannon CP, Henry TD, Schweiger MJ, Haugland JM, McKendall GR, Shah PK, et al. Current management of ST elevation myocardial infarction and outcome of thrombolytic ineligible patients: results of the multicenter TIMI 9 Registry (abstract). J Am Coll Cardiol 1995; Special Issue:231–232A.Google Scholar
  37. 37.
    Every NR, Larson EB, Litwin PE, Maynard C, Fihn SD, Eisenberg MS, et al. The association between on-site cardiac catheterization facilities and the use of coronary angiography after acute myocardial infarction. N Engl J Med 1993; 329: 546–551.PubMedCrossRefGoogle Scholar
  38. 38.
    Every NR, Parson LS, Fihn SD, Larson EB, Maynard C, Hallstrom AP, et al. Long-term outcome in acute myocardial infarction patients admitted to hospitals with and without on-site cardiac catheterization facilities. Circulation 1997; 96: 1770–1775.PubMedCrossRefGoogle Scholar
  39. 39.
    Blustein J. High-technology cardiac procedures. The impact of service availability on service use in New York State. JAMA 1993; 270: 344–349.PubMedCrossRefGoogle Scholar
  40. 40.
    Rouleau JL, Moye LA, Pfeffer MA, Arnold JMO, Berstein V, Cuddy T, et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. N Engl J Med 1993; 328: 779–784.PubMedCrossRefGoogle Scholar
  41. 41.
    Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995; 333: 565–572.PubMedCrossRefGoogle Scholar
  42. 42.
    Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB, et al. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med 1994; 331: 1130–1135.PubMedCrossRefGoogle Scholar
  43. 43.
    Tu JV, Pashos CL, Naylor D, Chen E, Normand S-L, Newhouse JP, et al. Use of cardiac procedures and outcomes in elderly patients with mycardial infarction in the United States and Canada. JAMA 1997; 336: 1500–1505.Google Scholar
  44. 44.
    TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989; 320: 618–627.CrossRefGoogle Scholar
  45. 45.
    Williams DO, Braunwald E, Knatterud G, Babb J, Bresnahan J, Greenberg M, et al. One-year results of the Thrombolysis in Myocardial Infarction Investigation (TIMI) phase II trial. Circulation 1992; 85: 533–542.PubMedCrossRefGoogle Scholar
  46. 46.
    Terrin ML, Williams DO, Kleiman NS, Willerson J, Mueller HS, Desvignes-Nickens P, et al. Two-and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. J Am Coll Cardiol 1993; 22: 1763–1772.PubMedCrossRefGoogle Scholar
  47. 47.
    Goldman L. Cost-effective strategies in cardiology. In: Braunwald E, ed. Heart Disease. A Textbook of Cardiovascular Medicine. WB Saunders, Philadelphia, 1992, pp. 1694–1707.Google Scholar
  48. 48.
    SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. SWIFT trial of delayed elective intervention v. conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. BMJ 1991;302:555–560.Google Scholar
  49. 49.
    Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331–336.CrossRefGoogle Scholar
  50. 50.
    Zaret BL, Wackers FJT, Terrin ML, Forman SA, Williams DO, Knatterud GL, et al. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II study. J Am Coll Cardiol 1995; 26: 73–79.PubMedCrossRefGoogle Scholar
  51. 51.
    Nicod P, Gilpin E, Dittrich H, Chappuis F, Ahnve S, Engler R, et al. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. Am J Cardiol 1988; 61: 1165–1171.PubMedCrossRefGoogle Scholar
  52. 52.
    Silver MT, Rose GA, Paul SD, O’Donnell CJ, O’Gara PT, Eagle KA. A clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Ann Intern Med 1994; 121: 750–756.PubMedCrossRefGoogle Scholar
  53. 53.
    Tobin K, Stomel R, Harber D, Karavite D, Eagle K. Validation of a clinical prediction rule for predicting left ventricular function post acute mycardial infarction in a community hospital setting (abstract). J Am Coll Cardiol 1996; 27 (Suppl. A): 318A.CrossRefGoogle Scholar
  54. 54.
    Krumholtz HM, Howes CJ, Murillo JE, Vaccarino LV, Radford MJ, Ellerbeck EF. Validation of a clinical prediction rule for left ventricular ejection fraction after myocardial infarction in patients >65 years old. Am J Cardiol 1997; 80: 11–15.CrossRefGoogle Scholar
  55. 55.
    Nickerson NJ, Murphy SF, Kouchoukos NT, Daily BB, Schechtman KB, Davila-Roman VG. Predictors of early discharge after cardiac surgery and its cost-effectiveness (abstract). J Am Coll Cardiol 1996; 27: 264A.Google Scholar
  56. 56.
    Newby LK, Califf RM, for the GUSTO Investigators. Redefining uncomplicated myocardial infarction in the thrombolytic era (abstract). Circulation 1994; 90: I - 110.Google Scholar
  57. 57.
    Cannon CP, Antman EM, Gibson CM, Paul SD, Braunwald E. Critical pathway for acute ST segment elevation myocardial infarction: evaluation of the potential impact in the TIMI 9 registry (abstract). J Am Coll Cardiol 1998; 31 (Suppl. A): 192A.CrossRefGoogle Scholar
  58. 58.
    Hillis LD, Forman S, Braunwald E, and the Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1990; 16: 313–315.PubMedCrossRefGoogle Scholar
  59. 59.
    Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II. Circulation 1992; 85: 1254–1264.PubMedCrossRefGoogle Scholar
  60. 60.
    Mark DB, Sigmon K, Topol EJ, Kereiakes DJ, Pryor DB, Candela RJ, et al. Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy. Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry. Circulation 1991; 83: 1186–1193.PubMedCrossRefGoogle Scholar
  61. 61.
    Topol EJ, Bure K, O’Neill WW, Kewman DG, Kander NH, Shea MJ, et al. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. N Engl J Med 1988; 318: 1083–1088.PubMedCrossRefGoogle Scholar
  62. 62.
    Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1998; 31: 967–972.PubMedCrossRefGoogle Scholar
  63. 63.
    Goldman L, Cook EF, Brand DA, Lee TH, Rouan GW, Weisberg MC, et al. A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med 1988; 318: 797–803.PubMedCrossRefGoogle Scholar
  64. 64.
    Pozen MW, D’Agostino RB, Mitchell JB, et al. The usefulness of a predictive instrument to reduce inappropriate admissions to the coronary care unit. Ann Intern Med 1980; 92: 238–242.PubMedCrossRefGoogle Scholar
  65. 65.
    Topol EJ, Califf RM. Scorecard cardiovascular medicine. Its impact and future directions. Ann Intern Med 1994; 120: 65–70.PubMedCrossRefGoogle Scholar
  66. 66.
    Topol EJ, Block PC, Holmes DR, Klinke WP, Brinker JA. Readiness for the scorecard era in cardiovascular medicine (editorial). Am J Cardiol 1995; 75: 1170–1173.PubMedCrossRefGoogle Scholar
  67. 67.
    Cannon CP. Optimizing the treatment of unstable angina. J Thromb Thrombolysis 1995; 2: 205–218.PubMedCrossRefGoogle Scholar
  68. 68.
    Nichol G, Walls R, Goldman L, Pearson S, Hartley LH, Antman E, et al. A critical pathway for management of patients with acute chest pain at low risk for myocardial ischemia: recommendations and potential impact. Ann Intern Med 1997; 127: 996–1005.PubMedCrossRefGoogle Scholar
  69. 69.
    Zalenski RI, Rydman RJ, McCaren M, Roberts RR, Jovanovic B, Das K, et al. Feasibility of a rapid diagnostic protocol for an emergency department chest pain unit. Ann Emerg Med 1997; 29: 99–108.PubMedCrossRefGoogle Scholar
  70. 70.
    Tatum JL, Jesse RL, Kontos MC, Nicholson CS, Schmidt KL, Roberts CS, et al. Comprehensive strategy for the evaluation and triage of the chest pain patient. Ann Emerg Med 1997; 29: 116–125.PubMedCrossRefGoogle Scholar
  71. 71.
    Cannon CP, Lambrew CT, Tiefenbrunn AJ, French WJ, Gore JM, Weaver DW, et al. Influence of door-to-balloon time on mortality in primary angioplasty. Results in 3,648 patients in the Second National Registry of Myocardial Infarction (NRMI-2) (abstract). J Am Coll Cardiol 1996; 27 (Suppl. A): 61A - 62A.CrossRefGoogle Scholar
  72. 72.
    Cannon CP, Braunwald E. Time to reperfusion: the critical modulator in thrombolysis and primary angioplasty. J Thromb Thrombolysis 1996; 3: 109–117.Google Scholar
  73. 73.
    Schroder R, Dissmann R, Bruggemann T, Wegscheider K, Linderer T, Tebbe U, et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24: 384–391.PubMedCrossRefGoogle Scholar
  74. 74.
    Schroder R, Wegscheider K, Schroder K, Dissmann R, Meyer-Sabellek W, for the INJECT Trial Group. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol 1995; 26: 1657–1664.PubMedCrossRefGoogle Scholar
  75. 75.
    Tanasijevic MJ, Cannon CP, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, et al. Myoglobin, creatine kinase MB and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: Results from TIMI 10A. Am Heart J 1997; 134: 622–630.PubMedCrossRefGoogle Scholar
  76. 76.
    Tanasijevic M, Cannon CP, Wybenga DR, Fischer G, Grudzien C, McCabe CH, et al. Serum myoglobin, cardiac troponin I, and creatine kinase (CK)-MB, to assess reperfusion after thrombolysis for acute myocardial infarction. Results from TIMI 10B (abstract). Circulation 1997; 96 (Suppl. I): I - 332.Google Scholar
  77. 77.
    Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, St. Goar FG, et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI Stent pilot trial. J Am Coll Cardiol 1998; 31: 23–30.PubMedCrossRefGoogle Scholar
  78. 78.
    Topol EJ. RAPPORT: a trial of abciximab as an adjunct to primary PTCA. Presented at the George Washington University 13th International Workshop: Thrombolysis and Interventional therapy in Acute Myocardial Infarction. Orlando, FL, 1997.Google Scholar
  79. 79.
    Cannon CP, McCabe CH, Stone PH, Rogers WJ, Schactman M, Thompson BW, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. J Am Coll Cardiol 1997; 30: 133–140.PubMedCrossRefGoogle Scholar
  80. 80.
    Braunwald E. Unstable angina: a classification. Circulation 1989; 80: 410–414.PubMedCrossRefGoogle Scholar
  81. 81.
    The Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498–1505.CrossRefGoogle Scholar
  82. 82.
    The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:Google Scholar
  83. 83.
    The PURSUIT Trial Investigators. Inhibition of Platelet Glycoprotein IIb/IIIa with eptifibatide in patient with acute coronary syndromes. N Engl J Med 1998; 339: 436–443.CrossRefGoogle Scholar
  84. 84.
    Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342–1349.PubMedCrossRefGoogle Scholar
  85. 85.
    Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E, for the TACTICS-TIMI 18 Investigators. Invasive versus conservative strategies in unstable angina and non-Q wave myocardial infarction following treatment with Tirofiban: rationale and study design of the international TACTICS-TIMI 18 trial. Am J Cardiol 1998 (in press).Google Scholar
  86. 86.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.Google Scholar
  87. 87.
    Sacks RM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.PubMedCrossRefGoogle Scholar
  88. 88.
    Graff LG, Dallara J, Ross MA, Joseph AJ, Itzcovitz J, Andelman RP, et al. Impact on the care of the emergency department chest pain patient from the Chest Pain Evaluation Registry (CHEPER) Study. Am J Cardiol 1997; 80: 563–568.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Christopher P. Cannon
  • Patrick T. O’Gara

There are no affiliations available

Personalised recommendations